Codexis Reports Third Quarter 2022 Financial Results
Reiterates 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Nov….
Reiterates 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Nov….
Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve…
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a…
— Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application…
– Approximately $61 Million of International Sales in the Third Quarter – – Corporate Update…
— Conference call to be held Thursday, November 10, 2022, at 4:30 p.m. ET —…
Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to…
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
–Announced that the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE),…
– On track to report topline results from STS101 SUMMIT Phase 3 efficacy trial in…
• AMELI-01 (evaluating UCART123) abstract, selected for oral presentation, highlights that adding alemtuzumab was associated…
– Biomedical Advanced Research and Development Authority (BARDA) awarded contract to support pandemic preparedness for…
REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the…
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI),…
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
Inclusion of the 24-month data has the potential to strengthen the product profile at launch,…
Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2…
Company to Host Conference Call, November 10, 2022, at 4:30 p.m. ET SAN DIEGO, Nov….
– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced…